RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics

WORCESTER, Mass.–(BUSINESS WIRE)–RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, Inc., positive data were generated demonstrating that RXi’s sd-rxRNA™ technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

The parties have successfully applied RXi’s proprietary sd-rxRNA (self-delivering rxRNA) technology to create microRNA mimics, or artificial copies of microRNAs. In particular, they have demonstrated efficacy in down-regulating a reporter gene whose expression is controlled by the microRNA in cell culture model systems developed by miRagen. Increasing the level of particular microRNAs by using therapeutic mimics may treat certain diseases, including cardiovascular, cancer, inflammatory, fibrotic and metabolic disorders. This data will be presented in a poster at the upcoming Keystone Symposia’s MicroRNAs and Non-Coding RNAs and Cancer meeting February 11-16, 2011 and will be available on RXi’s website after the conference www.rxipharma.com.

(read the entire release… )

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

Add Comment